title: The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B.
abstract: The clinical application of salvianolic acid B (Sal B), a potential therapeutic agent for cardiovascular diseases isolated from Salvia miltiorrhiza, is greatly restricted by its short half-life and low bioavailability. To improve therapeutic effects and prolong the systemic circulation time of Sal B, liposomes, composed of soybean phosphatidylcholine and cholesterol were prepared by reverse-phase evaporation method. In addition, polyethylene glycol 2000-disteroylphosphoethanolamine (PEG-DSPE 2000) was included to give steric barrier to liposomes. A central composite design was employed to optimize liposomal formulation with high encapsulation efficiency and small particle size. Physicochemical characteristics such as particle size, zeta potential, encapsulation efficiency and in vitro release were investigated. In vivo pharmacokinetic properties of Sal B in beagle dogs and the effect of PEG on the blood circulation time of Sal B-loaded liposomes were also evaluated. An optimized formulation with encapsulation efficiency of 73.68% and mean particle size of 136.6nm were developed. Encapsulation of Sal B into conventional and PEGylated liposomes could prolong the half-life of Sal B by 5.8- and 17.5-fold and enhance the AUC(0-t) of Sal B by 6.7- and 13.3-fold compared with free Sal B, respectively. Therefore, the use of PEGylated liposomes could prolong the circulation time in blood and longevity effect of liposomes on Sal B was increased by PEG.
authors.affiliation: Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, PR China.
authors.forename: Lihong
authors.initials: L
authors.lastname: Zhang
authors.forename: Limei
authors.initials: L
authors.lastname: Han
authors.forename: Xun
authors.initials: X
authors.lastname: Sun
authors.forename: Dongyan
authors.initials: D
authors.lastname: Gao
authors.forename: Jing
authors.initials: J
authors.lastname: Qin
authors.forename: Jianxin
authors.initials: J
authors.lastname: Wang
mesh_terms: D000818:Animals; D001572:Benzofurans / Q000097:blood / Q000493:pharmacokinetics*; D001682:Biological Availability; D002214:Capsules; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002626:Chemistry, Pharmaceutical; D002784:Cholesterol / Q000737:chemistry; D004285:Dogs; D006207:Half-Life; D008081:Liposomes / Q000737:chemistry; D010316:Particle Size; D010713:Phosphatidylcholines / Q000737:chemistry; D010714:Phosphatidylethanolamines / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry*; D027561:Salvia miltiorrhiza / Q000737:chemistry*; D013025:Glycine max; D053630:Depsides
chemical_list: D001572:Benzofurans; D002214:Capsules; D002317:Cardiovascular Agents; D002784:Cholesterol; D008081:Liposomes; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D011092:Polyethylene Glycols; C107570:polyethylene glycol-distearoylphosphatidylethanolamine; C076944:salvianolic acid B; D053630:Depsides